ICONOVO AB PUBLISHES THE ANNUAL REPORT 2023 IN ENGLISH

The abbreviated annual report 2023 in English is attached to this press release and is now available on the company's website, www.iconovo.se. ContactsJohan Wäborg,…

Iconovo files patent application for inhaled GLP-1 products and initiates development of new obesity treatments

Iconovo AB (publ), which develops complete inhalation products for a global market, today announces that the company has filed a broad patent application…

Iconovo receives patent protection for ICOres® in China

Iconovo AB (publ), which develops complete inhalation products for a global market, today announces that the Chinese Patent Office intends to approve Iconovo's application for a patent for the inhalation platform ICOres®. ICOres® is already being used in several of Iconovo's customer projects, and this new patent strengthens the intellectual property rights, benefiting customers who will launch pharmaceutical products based on the company's unique inhaler in the future.

QUARTERLY REPORT Q1-2024

Q1 2024 | 25 April 2024

Iconovo to present positive data from a feasibility study on Nanofitins® in ICOone®

Iconovo AB (publ), which develops complete inhalation products for a global market, and Affilogic (Nantes, France) today announce that Iconovo will present positive results from a feasibility study with a Nanofitin®-based biologic drug against respiratory virus using ICOone®. The study is a part of the previously communicated feasibility agreement between the companies, aimed at developing a new treatment for lung diseases. The study results will be presented at Respiratory Drug Delivery (RDD®) 2024, which takes place in Tucson, Arizona, on May 5-9, 2024.

Iconovo receives grant of SEK 680,000 from Innowwide for market efforts in South Korea

Iconovo AB (publ), which develops complete inhalation products for a global market, today announces that the company will receive a grant of SEK 680,000 from Innowwide. The grant will be used to carry out a market study to introduce the company's services and products to the South Korean market. The project will be carried out during the period April to September 2024 and is part of the Iconovo Accelerator program that the company has previously communicated.

YEAR-END REPORT JANUARY-DECEMBER 2023

Q4 2023 | 15 February 2024

Iconovo carries out a directed share issue of SEK 33.3 million, partly subject to subsequent approval by the Extraordinary General Meeting, and brings forward the publication of the year-end report

Iconovo AB (“Iconovo” or the “Company”) carries out a directed share issue of 4,162,500 shares at a subscription price of SEK 8.0 per share (the “Share Issue”). The participants in the share issue include, amongst others, the existing shareholders Gerald Engström, Fjärde AP-fonden, Andra AP-fonden and Cicero Fonder. Furthermore, the Company’s shareholder base is broadened by participation from, amongst others, Landia and Bolite. Through the Share Issue, the Company will receive gross proceeds of SEK 33.3 million before transaction costs. Part of the Share Issue, corresponding to SEK 14.5 million of the gross proceeds before transaction costs, is conditional upon subsequent approval by an Extraordinary General Meeting to be held on March 6, 2024. Notice of the Extraordinary General Meeting will be announced in a separate press release. Due to the Share Issue, the Board of Directors has decided to bring forward the publication of the Company’s year-end report for the financial year 2023. The year-end report will be published immediately after this press release.

Iconovo signs additional contract with Kiox Pharma for the development of a new inhalable treatment for interstitial lung disease

Iconovo AB (publ), which develops complete inhalation products for a global market, today announces that the company has entered into an agreement to continue the formulation development with Danish rare lung disease company Kiox Pharma. This is a continuation of the collaboration between the companies that was announced last year. The new agreement entails revenues of SEK 2.7 million for Iconovo during 2024, in addition to the SEK 1.6 million that the company received during 2023.